ovarian cancer

Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial
Seeking Alpha
Tue, 12/6/22 - 10:31 am
CompuGen
COM701
Bristol Myers Squibb
Opdivo
ovarian cancer
platinum-resistant ovarian cancer
In free fall, Clovis defaults on loan and agrees to further restrict Rubraca use
Fierce Pharma
Mon, 12/5/22 - 11:07 am
Clovis Oncology
Rubraca
FDA
ovarian cancer
With the walls closing in for Clovis, FDA demands ovarian cancer restriction for Rubraca
Fierce Biotech
Thu, 11/17/22 - 10:52 am
Clovis Oncology
Rubraca
ovarian cancer
FDA
FDA bestows accelerated approval on ImmunoGen's ovarian cancer drug, with confirmatory answer coming soon
Endpoints
Tue, 11/15/22 - 10:41 am
Immunogen
FDA
ovarian cancer
mirvetuximab soravtansine
GSK Restricts the Use of PARP Inhibitor in Ovarian Cancer at the FDA's Request
BioSpace
Sun, 11/13/22 - 07:07 pm
GSK
ovarian cancer
Zejula
PARP inhibitors
FDA
ImmunoGen commercial chief to withdraw before drug launch
Medical Marketing and Media
Fri, 11/4/22 - 10:27 am
Immunogen
mirvetuximab soravtansine
ovarian cancer
A startup plans an IPO to give a shelved Lilly drug another shot
BioPharma Dive
Wed, 10/19/22 - 10:39 am
Acrivon Therapeutics
IPOs
Eli Lilly
prexasertib
ovarian cancer
endometrial cancer
bladder cancer
precision medicine
As Rubraca faces questions in ovarian cancer, Clovis trots out a prostate cancer partial win
Fierce Pharma
Mon, 10/3/22 - 11:30 pm
Clovis Oncology
Rubraca
ovarian cancer
prostate cancer
AstraZeneca, Merck withdraw Lynparza's late-line ovarian cancer nod amid PARP inhibitor death concerns
Fierce Pharma
Sun, 09/25/22 - 02:28 pm
AstraZeneca
Merck
Lynparza
ovarian cancer
Celsion’s Phase I/II ovarian cancer trial completes subject enrolment
Clinical Trials Arena
Fri, 09/16/22 - 10:14 am
Celsion
ovarian cancer
GEN-1
clinical trials
Undeterred by FDA warning, desperate Clovis seeks Rubraca nod in front-line ovarian cancer
Fierce Pharma
Wed, 09/14/22 - 09:47 am
Clovis Oncology
Rubraca
FDA
ovarian cancer
GSK’s Zejula offers lasting PFS benefit in Phase III ovarian cancer trial
Clinical Trials Arena
Mon, 09/12/22 - 11:34 pm
GSK
Zejula
ovarian cancer
clinical trials
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
Yahoo Finance
Fri, 09/9/22 - 11:03 am
ESMO
Adaptimmune
clinical trials
ADP-A2M4CD8
ovarian cancer
head and neck cancer
urothelial cancer
Anixa starts subject treatment in Phase I ovarian cancer cell therapy trial
Clinical Trials Arena
Tue, 08/16/22 - 11:12 am
Anixa Biosciences
clinical trials
CAR-T
ovarian cancer
Clovis, in need of cash or deals now to stem looming financial challenges, looks to pipeline for ideas
Fierce Biotech
Tue, 08/9/22 - 06:29 am
Clovis Oncology
Rubraca
ovarian cancer
funding
Gene therapy for ovarian cancer fails PhIII study — sinking VBL Therapeutics' shares
Endpoints
Wed, 07/20/22 - 09:33 am
VBL Therapeutics
gene therapy
ovarian cancer
VB-111
ofra-vec
ASCO: Clovis CEO defends Rubraca's ovarian cancer win as FDA wants more assurance
Fierce Pharma
Mon, 06/6/22 - 09:57 am
ASCO 2022
Clovis
Rubraca
ovarian cancer
FDA
Roche pays Repare $125M to join Big Pharma peers in cancer race
Fierce Biotech
Thu, 06/2/22 - 10:36 am
Roche
cancer
ovarian cancer
Repare Therapeutics
ASCO Preview: Immutep, InxMed and Faron Release New Clinical Findings
BioSpace
Tue, 05/31/22 - 10:49 am
ASCO 2022
IMMUTEP
non-small cell lung cancer
InxMed
ovarian cancer
Faron Pharmaceuticals
solid tumors
Researchers Use Emerging Ovarian Cancer Biomarker to Develop New Blood Test for Ovarian Cancer
Xtalks
Tue, 05/10/22 - 10:41 am
diagnostics
ovarian cancer
biomarkers
FDA

Pages